Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-03-27, Stock:NVS, The news for the past five days is as follows:
2018-03-20: NEWS1: Novartis Sales Reps Will Testify About Lavish Meals, U.S. Says.NEWS2: The Swiss Stock Market Recovered Some Lost Ground.NEWS3: The Swiss Stock Market Recovered Some Lost Ground.NEWS4: Novartis Partners With Harvard To Develop Biomaterial Systems.NEWS5: Novartis Partners With Harvard To Develop Biomaterial Systems.
2018-03-21: NEWS1: Novartis Signs Agreement With Canadian Cannabis Company Tilray Regarding Med Pot.NEWS2: Teva Sued by Corcept Therapeutics over Patent Infringement Claim.NEWS3: Latest Stock Recommendations on TEVA: Mostly ‘Holds’.NEWS4: Notable ETF Inflow Detected - VEU, NSRGY, VIS, NVS.NEWS5: Notable ETF Inflow Detected - VEU, NSRGY, VIS, NVS.NEWS6: A Look at Akcea Therapeutics’ Product Pipeline.NEWS7: Exploring Akcea Therapeutics’ Cash Flows.NEWS8: GlaxoSmithKline prescribes commercial reboot for pharma division.NEWS9: The Swiss Stock Market Dropped On Weakness Of Bank Stocks.NEWS10: The Swiss Stock Market Dropped On Weakness Of Bank Stocks.NEWS11: Better Buy: Amgen Inc. vs. Gilead Sciences, Inc..NEWS12: Better Buy: Amgen Inc. vs. Gilead Sciences, Inc..NEWS13: GlaxoSmithKline prescribes commercial reboot for pharma division.NEWS14: Regeneron Eylea Hits 24-Week Primary Endpoint in Study.NEWS15: Regeneron Eylea Hits 24-Week Primary Endpoint in Study.
2018-03-22: NEWS1: 4 Reasons Why Glaxo (GSK) Stock Can be a Great Pick in '18.NEWS2: 4 Reasons Why Glaxo (GSK) Stock Can be a Great Pick in '18.NEWS3: 30 Most Obese Countries In The World in 2018: Biggest Anti-Obesity Drug Markets.NEWS4: Roche's (RHHBY) Lucentis 0.3 mg PFS Receives FDA Approval.NEWS5: Roche's (RHHBY) Lucentis 0.3 mg PFS Receives FDA Approval.NEWS6: Biotech Winners And Losers From Congress' Latest Funding Bill.NEWS7: 4 Reasons Why Glaxo (GSK) Stock Can be a Great Pick in &apos;18.NEWS8: US Generics Market Consolidation Continues to Affect Teva.NEWS9: Roche&apos;s (RHHBY) Lucentis 0.3 mg PFS Receives FDA Approval.NEWS10: The Swiss Stock Market Fell On Trade War Anxiety.NEWS11: The Swiss Stock Market Fell On Trade War Anxiety.NEWS12: Exploring the Financial Performance of Akcea Therapeutics.NEWS13: FENC On Fast Track, SPHS To Report Data In Q2, REGN, ALNY Team Up For NASH.NEWS14: FENC On Fast Track, SPHS To Report Data In Q2, REGN, ALNY Team Up For NASH.
2018-03-23: NEWS1: Pharma Stock Roundup: ABBV's Rova-T Disappoints, J&J Unit Gets Buyout Offer.NEWS2: Pharma Stock Roundup: ABBV's Rova-T Disappoints, J&J Unit Gets Buyout Offer.NEWS3: Will This Coming IPO Biotech Undercut Gilead, Novartis In Cancer Drugs?.NEWS4: Cancer Space Roundup: NVS' Tasigna & SGEN's Adcetris Label Expansions in Focus.NEWS5: Cancer Space Roundup: NVS' Tasigna & SGEN's Adcetris Label Expansions in Focus.NEWS6: Teva Is Implementing This Strategy as Part of Its Restructuring.NEWS7: Cancer Space Roundup: NVS&apos; Tasigna & SGEN&apos;s Adcetris Label Expansions in Focus.NEWS8: Key Updates on Teva’s Restructuring Plan Progress.NEWS9: The Swiss Stock Market Dropped Further On Trade Concerns.NEWS10: The Swiss Stock Market Dropped Further On Trade Concerns.NEWS11: Incyte’s Revenue Stream in 4Q17.NEWS12: Sandoz: CHMP Adopts Positive Opinion For Infliximab - Quick Facts.NEWS13: Sandoz: CHMP Adopts Positive Opinion For Infliximab - Quick Facts.NEWS14: Novartis' Tasigna Approved By FDA To Treat Children With Rare Form Of Leukemia.NEWS15: Novartis' Tasigna Approved By FDA To Treat Children With Rare Form Of Leukemia.NEWS16: Novartis: Phase III Data Shows Siponimod Improves Outcomes In SPMS Patients.NEWS17: Novartis: Phase III Data Shows Siponimod Improves Outcomes In SPMS Patients.
2018-03-26: NEWS1: Merck, Eisai Get Japanese Nod for Lenvima Label Expansion.NEWS2: Merck, Eisai Get Japanese Nod for Lenvima Label Expansion.NEWS3: Novartis CEO on China Growth, Technology Usage and R&D.NEWS4: Novartis CEO Sees China Business Doubling Over Five Years.NEWS5: Novartis CEO Sees China Business Doubling Over Five Years.NEWS6: Novartis CEO Aims to Double China Sales on Faster Drug Approvals.NEWS7: Exploring Xencor’s Revenue Trend.NEWS8: Xencor’s Promising Research Pipeline.NEWS9: Novartis Gets Positive CHMP Opinion on Biosimilar Remicade.NEWS10: Novartis Gets Positive CHMP Opinion on Biosimilar Remicade.NEWS11: AI. Telemedicine. Quantum. New Novartis Boss Says Tech Will Finally Change The Drug Biz.NEWS12: Novartis Gets Positive CHMP Opinion on Biosimilar Remicade.NEWS13: Will Teva’s Fremanezumab Be Delayed due to Troubles at Celltrion?.NEWS14: Incyte’s Collaborations and Developments in 2018.NEWS15: The Swiss Stock Market Finished Lower After Late Pullback.NEWS16: The Swiss Stock Market Finished Lower After Late Pullback.NEWS17: Incyte’s Jakafi in 2017.

Answer: Decrease